Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.

ABSTRACT:

SUBMITTER: Tang Q 

PROVIDER: S-EPMC10845935 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature